The Weekly Term Sheet (46)
The biotech sector experienced one of its most intense dealmaking periods of 2025 during November 10-15, with over $25 billion
Royalty Financing as Defensive Capital: A Study in Takeover Deterrence
Introduction: Raising Capital for Defense
In the biotech industry's recent downturn, many companies have faced plummeting valuations – over
Fund of the week: Royalty Pharma
Executive Summary
Royalty Pharma (Nasdaq: RPRX) represents a paradox in modern pharmaceutical finance: a company that has simultaneously constructed formidable
Company of the Week: Braveheart Bio
With a name like Braveheart, this San Francisco-based biotech is showing plenty of heart (and courage) as it launches into
The Geopolitical Royalty: Structuring and De-risking Cross-Border Biotech Revenue Streams Between China and the West
A New Axis of Royalty Flows
China's biotech industry has become an increasingly vital node in global pharmaceutical
From Ivory Tower to Wall Street: Monetizing University Biotech Royalties
A scientist in a university lab toils over a breakthrough therapy. Years later, that discovery becomes a best-selling drug, delivering
Navigating Regulatory and Reimbursement Disruption: How Accelerated Approvals and Pricing Reforms Are Reshaping Pharmaceutical Royalty Valuations
Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty
The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory
The Weekly Term Sheet (45)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Return of Royalty
On 19 November, as the Jefferies London Healthcare Conference closes for the day, a different conversation begins. Registration for our
Fund of the Week: Lilly Ventures – Eli Lilly's Strategic Biotech Investor
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
